{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:13:59Z","timestamp":1792451639818,"version":"4.5.0"},"reference-count":25,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The primary objective of this study was to ascertain the acceptance, initiation, implementation and treatment completion rates of tuberculosis (TB) preventive therapy (TPT) using 3HP (INH\u2010Rifapentine) among household contacts of microbiologically confirmed drug sensitive TB cases on anti\u2010tubercular treatment under programmatic real\u2010world settings. The secondary objectives were to estimate the prevalence and predictors of latent TB infection (LTBI) in household contacts of the index TB cases. We also ascertained the safety profile of the 3HP TPT regimen in the household contacts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This prospective observational study was conducted at 10\u2009TB chest clinics in Delhi, India during 2022\u20132023. Household contacts aged 14 and older who tested positive for TB infection on a Tuberculin Skin test were initiated on the 3HP regimen. Logistic regression was performed by including statistically significant independent variables in multiple prediction models. <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 was considered statistically significant. STATA, version 15.1, was used to compute all analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1067 (84.68%) eligible contacts of microbiologically confirmed, drug sensitive TB cases underwent screening with tuberculin skin test (TST), 614 (95.6%) LTBI positive contacts accepted the initiation of TPT, and 564 (91.8%) of those initiated on TPT completed the treatment. The major reason for refusal of screening was the lack of perception of risk of TB disease due to asymptomatic status. The prevalence of LTBI positivity through TST was 61.5% (95% CI, 58.5%, 64.4%). Adverse events were reported by 195 (31.8%) contacts initiated on 3HP of which 20 participants discontinued TPT. None of the sociodemographic factors showed a significant association with LTBI positivity (except age) or TPT completion rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>LTBI management with 3HP is feasible among adolescent and adult household contacts in India with high rates of adherence from initiation until treatment completion. The maximum attrition of participants occurred at the time of screening for LTBI using TST.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tmi.13940","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T07:09:29Z","timestamp":1697872169000},"page":"890-900","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Implementation of <scp>tuberculosis<\/scp> preventive therapy with INH\u2010Rifapentine (<scp>3HP)<\/scp> for latent tuberculosis infection management in household tuberculosis contacts in India: A prospective study"],"prefix":"10.1111","volume":"28","author":[{"given":"Nandini","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Community Medicine Maulana Azad Medical College  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritika","family":"Bakshi","sequence":"additional","affiliation":[{"name":"Department of Community Medicine Maulana Azad Medical College  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-8720","authenticated-orcid":false,"given":"Saurav","family":"Basu","sequence":"additional","affiliation":[{"name":"Indian Institute of Public Health\u2014Delhi Public Health Foundation of India  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrunali","family":"Zode","sequence":"additional","affiliation":[{"name":"Indian Institute of Public Health\u2014Delhi Public Health Foundation of India  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema","family":"Arora","sequence":"additional","affiliation":[{"name":"National Tuberculosis Elimination Program, Government of NCT  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Khanna","sequence":"additional","affiliation":[{"name":"National Tuberculosis Elimination Program, Government of NCT  New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,21]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"WHO.The end TB strategy.https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/the-end-tb-strategy"},{"key":"e_1_2_13_3_1","unstructured":"WHO.Global TB report 2022.https:\/\/www.who.int\/teams\/global\u2010tuberculosis\u2010programme\/tb\u2010reports\/global\u2010tuberculosis\u2010report\u20102022\/tb\u2010disease\u2010burden\/2\u20101\u2010tb\u2010incidence"},{"key":"e_1_2_13_4_1","volume-title":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management","year":"2018"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.epidem.2019.10038"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijtb.2018.10.006"},{"key":"e_1_2_13_7_1","volume-title":"South\u2010East Asia regional action plan on programmatic management of latent tuberculosis infection","year":"2018"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003060"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2016.11.006"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38182"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6725a5"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000000605"},{"key":"e_1_2_13_13_1","unstructured":"Government of India.India. TB report 2022. Available from:https:\/\/tbcindia.gov.in\/WriteReadData\/IndiaTBReport2022\/TBAnnaulReport2022.pdf"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.ijmr_382_23"},{"key":"e_1_2_13_15_1","unstructured":"Government of India.RNTCP. National strategic plan for tuberculosis elimination.2017."},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy265"},{"key":"e_1_2_13_17_1","unstructured":"National TB Elimination Programme.Central TB Division. Guidelines for Programmatic Management of Tuberculusosis Preventive Treatment in India 2021. Available from:https:\/\/tbcindia.gov.in\/WriteReadData\/l892s\/Guidelines%20for%20Programmatic%20Management%20of%20Tuberculosis%20Preventive%20Treatment%20in%20India.pdf"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.21.0676"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.14910"},{"issue":"1","key":"e_1_2_13_20_1","first-page":"2e6","article-title":"Mantoux test and its interpretation. Indian","volume":"3","author":"Nayak S","year":"2012","journal-title":"Dermatol Online J"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217104"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad219"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00034-13"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/tmi.13693"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2377-"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/109019817400200405"}],"container-title":["Tropical Medicine &amp; International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tmi.13940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T08:31:57Z","timestamp":1702974717000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tmi.13940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,21]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1111\/tmi.13940"],"URL":"https:\/\/doi.org\/10.1111\/tmi.13940","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,21]]},"assertion":[{"value":"2023-10-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}